Biogen Idec, Inc.

Datamonitor's Biogen Idec, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.

Biogen Idec is engaged in the development, manufacturing, and commercialization of novel therapies in the areas of oncology, neurology and immunology. The company's key products include Avonex and Rituxan. The company primarily operates in the US and Europe. It is headquartered in Cambridge, Massachusetts and employs 3,750 people. The company recorded revenues of $2,683 million during the fiscal year ended December 2006, an increase of 10.8% over 2005. The operating profit of the company was $440 million during fiscal year 2006, an increase of 86.4% over 2005. The net profit was $217.5 million in fiscal year 2006, an increase of 35.3% over 2005.

Scope of the Report

• Provides all the crucial company information required for business and competitor intelligence needs
• Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
• Data is supplemented with details on the company's history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement

Reasons to Purchase

• Support sales activities by understanding your customers' businesses better
• Qualify prospective partners and suppliers
• Keep fully up to date on your competitors' business structure, strategy and prospects
• Obtain the most up to date company information available